Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

SBK: Hiroyuki Seki: "we have been out of World Superbike 10 years and we are still learning. The tyres have evolved and we ...

The North Atlantic Treaty Organization (NATO) is the formalization of this relationship, although the “collective west” has often acted as a unit outside this organization to deploy disproportionate ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

While architectural, museum-worthy nail art is a delight to behold and just as fun to wear, some folks are in the camp of ...

As Meghan’s new Netflix show airs for the first time, Tanya Gold explores the complex, heart-breaking and deeply unhealthy ...

Callista’s hobo bag has all the storage you’d ever need. Perfect for pocket-lovers, this bag ensures all your daily ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The clinical-stage ...